{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:31:18Z","timestamp":1772569878297,"version":"3.50.1"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2019,7,12]]},"abstract":"<jats:sec><jats:title\/><jats:p>Bisphosphonates (BPs) are stable analogues of the Inorganic Pyrophosphate (PPi), an endogenous regulator of bone mineralization, which can resist the hydrolysis in the gastrointestinal tract. Their conformation allows targeting the bone as a result of their three-dimensional structure, which makes them primary agents against osteoclast-mediated bone loss. They are used in many bone pathological conditions, like bone metastasis, because of its ability to modulate bone metabolism into a less favorable place to cancer cell growth, through the inhibition of osteoclastogenesis and bone resorption. This review is focused on the mechanisms of action through which BPs affect the cellular activity and survival, mainly on their antitumoral effects. In conclusion, BPs are considered the primary therapy for skeletal disorders due to its high affinity for bone, but now they are also considered as potential antitumor agents due to its ability to induce tumor cell apoptosis, inhibition of cell adhesion, invasion and proliferation, modulation of the immune system to target and eliminate cancer cells as well as affect the angiogenic mechanisms. Like any other drug, they also have some adverse effects, but the most common, the acute phase reaction, can be minimized with the intake of calcium and vitamin D.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389557519666190424163044","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T15:41:28Z","timestamp":1556206888000},"page":"988-998","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects"],"prefix":"10.2174","volume":"19","author":[{"given":"Sonia","family":"Teixeira","sequence":"first","affiliation":[{"name":"Laboratory for Bone Metabolism and Regeneration, Faculty of Dental Medicine, University of Porto, Porto, Portugal"}]},{"given":"Luis","family":"Branco","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Faculdade de Ciencias e Tecnologia, Universidade Nova de Lisboa, Portugal"}]},{"given":"Maria H.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Laboratory for Bone Metabolism and Regeneration, Faculty of Dental Medicine, University of Porto, Porto, Portugal"}]},{"given":"Jo\u00e3o","family":"Costa-Rodrigues","sequence":"additional","affiliation":[{"name":"Laboratory for Bone Metabolism and Regeneration, Faculty of Dental Medicine, University of Porto, Porto, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","volume":"4","author":"Fleisch H.","year":"2002","unstructured":"Fleisch H. Development of bisphosphonates.","journal-title":"Breast Cancer Res"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","volume":"38","author":"Papapoulos S.E.","year":"2006","unstructured":"Papapoulos SE. Bisphosphonate actions: Physical chemistry revisited.","journal-title":"Bone"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"Drake M.T.","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice.","journal-title":"Mayo Clin Proc"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/187152012799014959","volume":"12","author":"Widler L.","year":"2012","unstructured":"Widler L, Jahnke W, Green JR. The chemistry of bisphosphonates: From antiscaling agents to clinical therapeutics.","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","volume":"119","author":"Russell R.G.","year":"2007","unstructured":"Russell RG. Bisphosphonates: Mode of action and pharmacology.","journal-title":"Pediatrics"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","volume":"61","author":"Lehenkari P.P.","year":"2002","unstructured":"Lehenkari PP, Kellinsalmi M, N\u00e4p\u00e4nkangas JP, Ylitalo KV, M\u00f6nkk\u00f6nen J, Rogers MJ, Azhayev A, V\u00e4n\u00e4nen HK, Hassinen IE. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.","journal-title":"Mol Pharmacol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"Russell R.G.","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy.","journal-title":"Osteoporos Int"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"Rogers M.J.","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates.","journal-title":"Cancer"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"Nancollas G.H.","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite.","journal-title":"Bone"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/mol.56.1.131","volume":"56","author":"Benford H.L.","year":"1999","unstructured":"Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.","journal-title":"Mol Pharmacol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.1543","volume":"27","author":"Roelofs A.J.","year":"2012","unstructured":"Roelofs AJ, Stewart CA, Sun S, B\u0142a\u017cewska KM, Kashemirov BA, McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates","journal-title":"J Bone Miner Res"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"S73S","DOI":"10.1016\/S8756-3282(99)00070-8","volume":"24","author":"Rogers M.J.","year":"1999","unstructured":"Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG. Molecular mechanisms of action of bisphosphonates.","journal-title":"Bone"},{"key":"ref=13","first-page":"481","volume":"3","author":"Sims N.A.","year":"2014","unstructured":"Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: A multitude of signals within the basic multicellular unit.","journal-title":"Bonekey Rep"},{"key":"ref=14","first-page":"23","volume":"34","author":"Tolia M.","year":"2014","unstructured":"Tolia M, Zygogianni A, Kouvaris JR, Meristoudis C, Margari N, Karakitsos P, Kokakis I, Kardamakis D, Papadimitriou C, Mystakidou K, Tsoukalas N, Kyrgias G, Armonis B, Filippiadis DK, Kelekis AD, Kelekis N, Kouloulias V. The key role of bisphosphonates in the supportive care of cancer patients.","journal-title":"Anticancer Res"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/1097-0142(20000615)88:12+<2952::AID-CNCR11>3.0.CO;2-M","volume":"88","author":"Fontana A.","year":"2000","unstructured":"Fontana A, Delmas PD. Markers of bone turnover in bone metastases.","journal-title":"Cancer"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2007.048868","volume":"61","author":"Datta H.K.","year":"2008","unstructured":"Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism.","journal-title":"J Clin Pathol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/adj.12140","volume":"59","author":"Bhatt R.N.","year":"2014","unstructured":"Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: Review of the literature and guidelines for dental management.","journal-title":"Aust Dent J"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cancergen.2015.03.008","volume":"208","author":"Karlic H.","year":"2015","unstructured":"Karlic H, Thaler R, Gerner C, Grunt T, Proestling K, Haider F, Varga F. Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.","journal-title":"Cancer Genet"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"Cremers S.C.","year":"2005","unstructured":"Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics\/ pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis.","journal-title":"Clin Pharmacokinet"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2265.1986.tb03254.x","volume":"24","author":"Fogelman I.","year":"1986","unstructured":"Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA. Absorption of oral diphosphonate in normal subjects.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/TCRM.S52291","volume":"9","author":"Pazianas M.","year":"2013","unstructured":"Pazianas M, Abrahamsen B, Ferrari S, Russell RG. Eliminating the need for fasting with oral administration of bisphosphonates.","journal-title":"Ther Clin Risk Manag"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"Russell R.G.","year":"2011","unstructured":"Russell RG. Bisphosphonates: The first 40 years.","journal-title":"Bone"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/j.0022-0337.2008.72.8.tb04568.x","volume":"72","author":"Mariotti A.","year":"2008","unstructured":"Mariotti A. Bisphosphonates and osteonecrosis of the jaws.","journal-title":"J Dent Educ"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.36076\/ppj.2011\/14\/E373","volume":"14","author":"Smith H.S.","year":"2011","unstructured":"Smith HS. Painful Osseous Metastases.","journal-title":"Pain Physician"},{"key":"ref=25","first-page":"23","volume":"34","author":"Tolia M.","year":"2014","unstructured":"Tolia M, Zygogianni A, Kouvaris JR, Meristoudis C, Margari N, Karakitsos P, Kokakis I, Kardamakis D, Papadimitriou C, Mystakidou K, Tsoukalas N, Kyrgias G, Armonis B, Filippiadis DK, Kelekis AD, Kelekis N, Kouloulias V. The key role of bisphosphonates in the supportive care of cancer patients.","journal-title":"Anticancer Res"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2174\/0929867023369998","volume":"9","author":"Vepsalainen J.J.","year":"2002","unstructured":"Vepsalainen JJ. Bisphosphonate prodrugs.","journal-title":"Curr Med Chem"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","volume":"147","author":"M\u00f6nkk\u00f6nen H.","year":"2006","unstructured":"M\u00f6nkk\u00f6nen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Veps\u00e4l\u00e4inen J, M\u00f6nkk\u00f6nen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","volume":"69","author":"Thompson K.","year":"2006","unstructured":"Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.","journal-title":"Mol Pharmacol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"Rogers M.J.","year":"2011","unstructured":"Rogers MJ, Crockett JC, Coxon FP, M\u00f6nkk\u00f6nen J. Biochemical and molecular mechanisms of action of bisphosphonates.","journal-title":"Bone"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"Roelofs A.J.","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: Current status.","journal-title":"Clin Cancer Res"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"Green J.R.","year":"2004","unstructured":"Green JR. Bisphosphonates: Preclinical review.","journal-title":"Oncologist"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","volume":"28","author":"Benford H.L.","year":"2001","unstructured":"Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts","journal-title":"Bone"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1593\/neo.10282","volume":"12","author":"Fournier P.G.","year":"2010","unstructured":"Fournier PG, Stresing V, Ebetino FH, Cl\u00e9zardin P. How do bisphosphonates inhibit bone metastasis","journal-title":"Neoplasia"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejcsup.2008.06.023","volume":"6","author":"Marra M.","year":"2008","unstructured":"Marra M, Santini D, Tonini G, Meo G, Zappavigna S, Facchini G, Morabito A, Abbruzzese A, Carten\u00ec G, Budillon A, Caraglia M. Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid.","journal-title":"EJC Suppl"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2407-9-38","volume":"9","author":"Knight L.A.","year":"2009","unstructured":"Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R, Dexel S, Reinhold U, Cree IA. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.","journal-title":"BMC Cancer"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1479-5876-11-303","volume":"11","author":"Xu X.L.","year":"2013","unstructured":"Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, Lu SB, Peng J. Basic research and clinical applications of bisphosphonates in bone disease: What have we learned over the last 40 years?","journal-title":"J Transl Med"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","volume":"48","author":"Clezardin P.","year":"2011","unstructured":"Clezardin P. Bisphosphonates\u2019 antitumor activity: An unravelled side of a multifaceted drug class.","journal-title":"Bone"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jbmr.5650090213","volume":"9","author":"Koopmans S.J.","year":"1994","unstructured":"Koopmans SJ, van der Wee-Pals L, Lowik CW, Papapoulos SE. Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: Application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate.","journal-title":"J Bone Miner Res"},{"key":"ref=39","first-page":"1157","volume":"32","author":"Israel O.","year":"1991","unstructured":"Israel O, Front D, Hardoff R, Ish-Shalom S, Jerushalmi J, Kolodny GM. SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis.","journal-title":"J Nucl Med"},{"key":"ref=40","first-page":"1478","volume":"41","author":"Carnevale V.","year":"2000","unstructured":"Carnevale V, Dicembrino F, Frusciante V, Chiodini I, Minisola S, Scillitani A. Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: Relevance to the pathogenesis of bone loss.","journal-title":"J Nucl Med"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"Porras A.G.","year":"1999","unstructured":"Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate.","journal-title":"Clin Pharmacokinet"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1177\/0022034510377791","volume":"89","author":"Boskey A.L.","year":"2010","unstructured":"Boskey AL, Coleman R. Aging and bone.","journal-title":"J Dent Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"Sato M.","year":"1991","unstructured":"Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.","journal-title":"J Clin Invest"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bone.2010.10.159","volume":"49","author":"Allen M.R.","year":"2011","unstructured":"Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don\u2019t know.","journal-title":"Bone"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2010.08.011","volume":"49","author":"Plotkin L.I.","year":"2011","unstructured":"Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice.","journal-title":"Bone"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","volume":"49","author":"Bellido T.","year":"2011","unstructured":"Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability.","journal-title":"Bone"},{"key":"ref=47","first-page":"S339","volume":"21","author":"Boland R.L.","year":"2006","unstructured":"Boland RL, Morelli S, Santillan G, Scodelaro P, Colicheo A, de Boland AR, Vyas K, Plotkin LI, Bellido T. Connexin 43 Is required for bisphosphonate-induced survival of osteoblastic cells but not for bisphosphonate binding.","journal-title":"J Bone Miner Res"},{"key":"ref=48","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/526236","volume":"2012","author":"Escudero N.D.","year":"2012","unstructured":"Escudero ND, Mandalunis PM. Influence of bisphosphonate treatment on medullary macrophages and osteoclasts: An experimental study.","journal-title":"Bone Marrow Res"},{"key":"ref=49","volume":"3","author":"Weivoda M.M.","year":"2014","unstructured":"Weivoda MM, Oursler MJ. The roles of small GTPases in osteoclast biology.","journal-title":"Orthop Muscular Syst"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4161\/sgtp.2.3.16488","volume":"2","author":"Taylor A.","year":"2011","unstructured":"Taylor A, Mules EH, Seabra MC, Helfrich MH, Rogers MJ, Coxon FP. Impaired prenylation of rab GTPases in the gunmetal mouse causes defects in bone cell function.","journal-title":"Small GTPases"},{"key":"ref=51","first-page":"25","volume":"1","author":"Zekri J.","year":"2003","unstructured":"Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid.","journal-title":"J Bone Oncol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jac\/dkg490","volume":"52","author":"Einav S.","year":"2003","unstructured":"Einav S, Glenn JS. Prenylation inhibitors: A novel class of antiviral agents.","journal-title":"J Antimicrob Chemother"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/AAC.01820-10","volume":"55","author":"Jord\u00e3o F.M.","year":"2011","unstructured":"Jord\u00e3o FM, Saito AY, Miguel DC, de Jesus Peres V, Kimura EA, Katzin AM. and antiplasmodial activities of risedronate and its interference with protein prenylation in","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","volume":"16","author":"Roelofs A.J.","year":"2010","unstructured":"Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: Molecular mechanisms of action and effects on bone cells, monocytes and macrophages.","journal-title":"Curr Pharm Des"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1021\/jm040209d","volume":"48","author":"Sanders J.M.","year":"2005","unstructured":"Sanders JM, Song Y, Chan JMW, Zhang Y, Jennings S, Kosztowski T, Odeh S, Flessner R, Schwerdtfeger C, Kotsikorou E, Meints GA, G\u00f3mez AO, Gonz\u00e1lez-Pacanowska F, Raker AM, Wang H, van Beek ER, Papapoulos SE, Morita CT, Oldfield E. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.","journal-title":"J Med Chem"},{"key":"ref=56","volume":"94","author":"Liu J.","year":"2015","unstructured":"Liu J, Huang W, Zhou R, Jia S, Tang W, Luo Y, Zhang J. Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer - A meta-analysis.","journal-title":"Medicine (Baltimore)"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-015-0634-8","volume":"17","author":"Santini D.","year":"2015","unstructured":"Santini D, Stumbo L, Spoto C, D\u2019Onofrio L, Pantano F, Iuliani M, Fioramonti M, Zoccoli A, Ribelli G, Virz\u00ec V, Vincenzi B, Tonini G. Bisphosphonates as anticancer agents in early breast cancer: Preclinical and clinical evidence.","journal-title":"Breast Cancer Res"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/jcb.23439","volume":"113","author":"Costa-Rodrigues J.","year":"2012","unstructured":"Costa-Rodrigues J, Moniz KA, Teixeira MR, Fernandes MH. Variability of the paracrine-induced osteoclastogenesis by human breast cancer cell lines.","journal-title":"J Cell Biochem"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10585-011-9387-7","volume":"28","author":"Costa-Rodrigues J.","year":"2011","unstructured":"Costa-Rodrigues J, Teixeira CA, Fernandes MH. Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: Is RANKL\/RANK signalling really important?","journal-title":"Clin Exp Metastasis"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1002\/jcb.23295","volume":"112","author":"Costa-Rodrigues J.","year":"2011","unstructured":"Costa-Rodrigues J, Fernandes A, Fernandes MH. Reciprocal osteoblastic and osteoclastic modulation in co-cultured MG63 osteosarcoma cells and human osteoclast precursors.","journal-title":"J Cell Biochem"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","volume":"88","author":"Guise T.A.","year":"2000","unstructured":"Guise TA. Molecular mechanisms of osteolytic bone metastases.","journal-title":"Cancer"},{"key":"ref=62","first-page":"749","volume":"12","author":"Mathew A.","year":"2014","unstructured":"Mathew A, Brufsky AM. The use of adjuvant bisphosphonates in the treatment of early-stage breast cancer.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/1097-0142(20000615)88:12+<3038::AID-CNCR21>3.0.CO;2-V","volume":"88","author":"Paterson A.H.","year":"2000","unstructured":"Paterson AH. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.","journal-title":"Cancer"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(15)61163-1","volume":"386","author":"Brufsky A.","year":"2015","unstructured":"Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence.","journal-title":"Lancet"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"Wood J.","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, Bellahc\u00e8ne A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1464-4096.2004.04831.x","volume":"94","author":"Coxon J.P.","year":"2004","unstructured":"Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells inhibition of protein prenylation.","journal-title":"BJU Int"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","volume":"1820","author":"Dedes P.G.","year":"2012","unstructured":"Dedes PG, Gialeli CH, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D, Tzanakakis GN, Karamanos NK. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.","journal-title":"Biochim Biophys Acta"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1582-4934.2012.01527.x","volume":"16","author":"Insalaco L.","year":"2012","unstructured":"Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, Russo A. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.","journal-title":"J Cell Mol Med"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","volume":"86","author":"Senaratne S.G.","year":"2002","unstructured":"Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells.","journal-title":"Br J Cancer"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"17989","DOI":"10.1073\/pnas.1421410111","volume":"111","author":"Yuen T.","year":"2014","unstructured":"Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu L, Kim S, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, Latif Y, Mujtaba S, Epstein S, Davies TF, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M. Bisphosphonates inactivate human EGFRs to exert antitumor actions.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"Gober H.J.","year":"2003","unstructured":"Gober HJ, Kistowska M, Angman L, Jen\u00f6 P, Mori L, De Libero G. Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells.","journal-title":"J Exp Med"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1479-5876-9-177","volume":"9","author":"Rogers T.L.","year":"2011","unstructured":"Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates.","journal-title":"J Transl Med"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00018-003-2297-3","volume":"60","author":"R\u00fcegg C.","year":"2003","unstructured":"R\u00fcegg C, Mariotti A. Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis.","journal-title":"Cell Mol Life Sci"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1535-7163.MCT-07-0311","volume":"6","author":"Scavelli C.","year":"2007","unstructured":"Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AML, Ribatti D, Dammacco F, Vacca A. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.","journal-title":"Mol Cancer Ther"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","volume":"278","author":"Bezzi M.","year":"2003","unstructured":"Bezzi M, Hasmim M, Bieler G, Dormond O, R\u00fcegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death.","journal-title":"J Biol Chem"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1096\/fj.01-0911fje","volume":"16","author":"P\u00e9cheur I.","year":"2002","unstructured":"P\u00e9cheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Cl\u00e9zardin P. Integrin \u03b1v\u03b23 expression confers on tumor cells a greater propensity to metastasize to bone.","journal-title":"FASEB J"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"Jagdev S.P.","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel.","journal-title":"Br J Cancer"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"Terpos E.","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A. European myeloma network guidelines for the management of multiple myeloma-related complications.","journal-title":"Haematologica"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00520-017-3583-1","volume":"25","author":"Qian Y.","year":"2017","unstructured":"Qian Y, Bhowmik D, Kachru N, Hernandez RK. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States.","journal-title":"Support Care Cancer"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2016.10.007","volume":"95","author":"Tr\u00e9mollieres F.A.","year":"2017","unstructured":"Tr\u00e9mollieres FA, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, P\u00e9rez-L\u00f3pez FR, van der Schouw YT, Senturk LM, Simoncini T, Stevenson JC, Stute P, Rees M. Osteoporosis management in patients with breast cancer: EMAS position statement.","journal-title":"Maturitas"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"Miller P.D.","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: A review.","journal-title":"J Bone Miner Res"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2040622315584114","volume":"6","author":"Saita Y.","year":"2015","unstructured":"Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: Current evidence and clinical implications.","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","volume":"12","author":"Maalouf N.M.","year":"2006","unstructured":"Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: Report of 3 cases and review of literature.","journal-title":"Endocr Pract"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T21:52:46Z","timestamp":1663365166000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171839\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,7,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666190424163044","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}